In-depth analysis Of Type 2 Diabetes Therapeutics in Asia-Pacific Markets to 2020 - PowerPoint PPT Presentation

Loading...

PPT – In-depth analysis Of Type 2 Diabetes Therapeutics in Asia-Pacific Markets to 2020 PowerPoint presentation | free to download - id: 701f0b-MWNjY



Loading


The Adobe Flash plugin is needed to view this content

Get the plugin now

View by Category
About This Presentation
Title:

In-depth analysis Of Type 2 Diabetes Therapeutics in Asia-Pacific Markets to 2020

Description:

Big Market Research presents this report which estimates the market size for 2013 and provides a forecast until 2020, and covers disease epidemiology, treatment algorithms, and treatment use patterns. Read The Full Report @ – PowerPoint PPT presentation

Number of Views:8
Slides: 9
Provided by: suzanneburns08
Category: Other

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: In-depth analysis Of Type 2 Diabetes Therapeutics in Asia-Pacific Markets to 2020


1
Type 2 Diabetes Therapeutics in Asia-Pacific
Markets to 2020
2
Summary
  • GBI Research, the leading business intelligence
    provider, has released its latest research, Type
    2 Diabetes Therapeutics in Asia-Pacific Markets
    to 2020 Increasing Uptake of Novel Drug Classes
    to Drive Market Growth, which provides insights
    into type 2 diabetes in the Asia-Pacific (APAC)
    markets of China, India, Japan and Australia.
  • The report estimates the market size for 2013 and
    provides a forecast until 2020, and covers
    disease epidemiology, treatment algorithms, and
    treatment use patterns. It also provides in-depth
    analysis of the pipeline molecules, clinical
    trial failure rates, and recent deals.
  • The report has been built using data and
    information sourced from proprietary databases,
    primary and secondary research and in-house
    analysis carried out by GBI Researchs team of
    industry experts

3
Report Description
  • In 2013, the value of the type 2 diabetes
    therapeutics market in APAC countries was an
    estimated 6.5 billion, and it is forecast to
    grow at a Compound Annual Growth Rate (CAGR) of
    7.1 between 2013 and 2020 to 10.5 billion.
  • This strong growth is due to the anticipated
    approval of products in relatively novel
    treatment classes, such as Glucagon-Like
    Peptide-1 (GLP-1) agonists, Dipeptidyl
    Peptidase-4 (DPP-4) inhibitors, and Sodium
    Glucose Transporter-2 (SGLT-2) inhibitors, as
    well as the growth of the prevalence population
    in the APAC region, particularly in India and
    China.
  • Read The Full Report _at_ http//www.bigmarketresearc
    h.com/type-2-diabetes-theratype-2-diabetes-therape
    utics-in-asia-pacific-to-2020-increasing-uptake-of
    -novel-drug-classes-to-drive-growthpeutics-in-asia
    -pacific-to-2020-increasing-uptake-of-novel-drug-c
    lasses-market

4
Scope
  • The report analyzes the treatment use patterns,
    market characterization, pipeline analysis and
    key licensing and co-development deals of the
    type 2 diabetes in the APAC markets of China,
    India, Japan, and Australia. It includes -
  • A brief introduction to type 2 diabetes,
    including its pathophysiology, etiology,
    diagnosis and treatment algorithms
  • In-depth analysis of currently marketed drugs for
    type 2 diabetes, including analysis of their
    safety, efficacy, treatment patterns, and
    strengths and weaknesses, as well as a heat map
    comparing them in terms of safety and efficacy
  • A comprehensive review of the pipeline for type 2
    diabetes, including individual analysis of a
    number of late-stage pipeline drugs that are
    likely to enter the market during the forecast
    period the pipeline is analyzed by Phase
    distribution, molecule type, program type,
    mechanism of action and molecular target

5
Key Market
  • Additional in-depth analysis of pipeline drug
    clinical trials by Phase, trial size, trial
    duration and program failure rate for each
    molecule type
  • Multi-scenario market forecast data to 2020,
    taking into account how the market might be
    affected by the introduction of new drugs, the
    expiry of key patents on current drugs, and the
    changes in disease epidemiology across the key
    developed markets
  • Discussion of the drivers of and barriers to
    market growth
  • In-depth analysis of all licensing and
    co-development deals that have occurred in the
    type 2 diabetes market since 2006
  • To Get More Details Enquire _at_ http//www.bigmarket
    research.com/report-enquiry/176579

6
Reasons to buy
  • The report will enhance your decision-making
    capability by allowing you to -
  • Understand the type 2 diabetes pipeline and the
    factors that indicate that it is becoming more
    innovative
  • Examine detailed profiles for promising pipeline
    products and gain an insight into how and with
    whom they are likely to compete in the market
  • Follow the trends in type 2 diabetes clinical
    trial size and duration in relation to industry
    averages
  • Assess the potential risk of future developmental
    programs for type 2 diabetes therapeutics,
    depending on the mechanism of action, by taking
    into account the recorded clinical trial failure
    rates
  • Examine the growth patterns expected for the type
    2 diabetes market over the forecast period and
    the countries that are expected to contribute the
    most to this growth, allowing you to devise a
    more effectively tailored country strategy
    through an understanding of key drivers and
    barriers
  • Accelerate and strengthen your market position by
    identifying key companies for strategic
    partnerships

7
Table Of Content
  • Introduction
  • Marketed Products
  • Type 2 Diabetes Market to 2020 Pipeline
    Products
  • Market Forecast to 2020
  • Deals and Strategic Consolidations
  • Appendix
  • Read The Full TOC _at_ http//www.bigmarketresearch.c
    om/type-2-diabetes-theratype-2-diabetes-therapeuti
    cs-in-asia-pacific-to-2020-increasing-uptake-of-no
    vel-drug-classes-to-drive-growthpeutics-in-asia-pa
    cific-to-2020-increasing-uptake-of-novel-drug-clas
    ses-market

8
Contact Us
Deep Joshi 5933 NE Win Sivers Drive, 205,
Portland, OR 97220 United States Direct 1
(617) 674-4143 Toll Free 1 (855) 711-1555 Fax
1 (855) 550-5975 Email help_at_bigmarketresearch
.com Web http//www.bigmarketresearch.com
About PowerShow.com